eanpages
  • General interest
    • All Executive Page EAN News EAN Congress news Interviews
      Executive Page

      Executive Page: Advocacy for brain health gaining momentum across the neurological landscape

      October 1, 2023

      EAN News

      EAN Contributes to Global Brain Health Agenda at UNGA78 with Leadership Presence

      September 28, 2023

      EAN News

      Earthquake in Morocco – EAN Statement

      September 11, 2023

      EAN News

      New EAN Coordinating Panel on Functional Neurological Disorders – Call for Applications

      September 7, 2023

      Executive Page

      Executive Page: Advocacy for brain health gaining momentum across the neurological landscape

      October 1, 2023

      Executive Page Dear EAN members, dear friends, It is my pleasure to give you an update on behalf of the EAN Scientific Committee following a busy year since my appointment as chair. It has been a privilege to be so deeply involved in the scientific activities of the EAN and to work closely with an amazing community of people who are so dedicated to the advancement of neurology. One of the strongest threads within that community is the EAN’s group of Scientific Panels, which are often referred to as the organisation’s ‘scientific backbone’. The panels have a hand in everything the EAN does from a scientific point of view, including coordinating clinical research, disseminating good practice, assisting in planning the EAN annual congress, supporting the EAN’s educational efforts, and producing guidelines that assist neurologists in daily practice. All of this work requires a considerable amount of oversight, and this is why each panel is run by its own Management Group, elected by the panel members. Being a part of one of these Management Groups (PDF) is an opportunity to play a direct part in determining the direction of scientific progress within Europe, and I am excited to say that the call for applications to stand for election will be announced in September. All panel members and EAN individual members are eligible to apply to be candidates, with the vote being held among the existing panel members in autumn. I would like to urge every neurologist with a passion for the scientific future of their special area of interest to consider standing for election to the relevant Management Group and to look out for the call for applications later this month. I can tell you from personal experience that fulfilling a role such as this within the structure of the EAN is a fascinating and extremely rewarding experience. The chance to take on such a unique leadership position should not be missed! The most satisfying aspect of being involved in the EAN’s organisational structure is surely seeing all the hard work and planning come to fruition when a small idea evolves into a newly launched project. One such example is the 1st EAN Science School, taking place in Salzburg next March. The idea of the Science School is to offer early career neurologists with an interest in translational research a new avenue for learning about basic pathomechanisms of neurological disorders. Application for this very first edition, on ‘Pathophysiology of disorders of the nervous system’, closed last week and we have been delighted with the level of interest. It was a pleasure to be part of the task force in charge of planning this new project and I look forward to seeing it officially transferred to the hands of the Scientific Committee after a successful event and evaluation in spring. Of our ongoing activities, one of the most significant is the EAN Neuro-covid Registry, which aims to collate epidemiological data on neurological manifestations in patients with COVID-19 infection reported by neurologists in outpatient services, emergency rooms, and hospital departments. We currently have 1,542 patients entered in the database, from 35 centres across 23 countries. So far, 29 patients have been followed for 12 months and 387 have completed the 6-months follow up. This is a decent start, but I would like to strongly encourage EAN members and their institutions to get involved and contribute cases to what will become an invaluable resource for neurologists and clinicians to improve care for Covid-19 patients. Finally, I would like share a word on a forthcoming collaboration between EAN and the Human Brain Project in December, that I think will interest a lot of EAN members. The EAN-EBRAINS joint workshop on ‘The future of medical data sharing in clinical neurosciences’ will be a three-day virtual event that aims to discuss issues and challenges associated with data sharing in Europe, from ethics to data safety and privacy, including those specific to data federation, such as the development and validation of federated algorithms. The whole workshop is completely free of charge and registration is open until 25 November, so please check out the details and sign up! I wish you all a healthy and pleasant autumn and I look forward to updating you again. Best wishes Thomas Berger Chair of the EAN Scientific Committee

      Executive Page: Management Group elections are coming – run for office and help shape our future!

      September 1, 2023

      Executive Page

      Executive Page: Thank you for making the EAN Congress 2023 a great success!

      July 24, 2023

      Executive Page

      Executive Page: Get ready for EAN 2023 in Budapest!

      June 1, 2023

      EAN News

      Executive Page: Advocacy for brain health gaining momentum across the neurological landscape

      October 1, 2023

      EAN News

      EAN Contributes to Global Brain Health Agenda at UNGA78 with Leadership Presence

      September 28, 2023

      EAN News

      Earthquake in Morocco – EAN Statement

      September 11, 2023

      EAN News

      New EAN Coordinating Panel on Functional Neurological Disorders – Call for Applications

      September 7, 2023

      EAN Congress news

      African Academy of Neurology features in Special Studio Session at EAN 2023

      July 25, 2023

      EAN Congress news

      Find photos, facts, figures and reports in our EAN Congress Review

      July 24, 2023

      EAN Congress news

      Executive Page: Thank you for making the EAN Congress 2023 a great success!

      July 24, 2023

      EAN Congress news

      Special Session on Guidelines at the EAN Congress: Meet the new EAN Guidelines

      July 21, 2023

      Interviews

      Video Interview: Prof. Mary Reilly, Moritz Romberg lecturer at EAN 2023

      July 4, 2023

      Interviews

      Video Interview: Mark Hallett, C. Brown-Séquard lecturer at EAN 2023

      July 3, 2023

      Interviews

      Video Interview: Josep Dalmau, Camillo Golgi Lecturer at EAN 2023

      July 2, 2023

      Interviews

      Video Interview: Dementia & Cognitive Disorders Panel Co-Chairs

      September 8, 2022

  • Academic/Scientific
    • All Paper of the Month Neurology updates COVID-19 Eur J Neurol Scientific Corner
      Academic/Scientific

      Open Call: EMA seeks new data partners for DARWIN EU – deadline 31 October

      September 29, 2023

      EAN News

      New EAN Coordinating Panel on Functional Neurological Disorders – Call for Applications

      September 7, 2023

      EAN News

      European Journal of Neurology to be fully open access from January 1 2024

      September 7, 2023

      Paper of the Month

      Research Paper of the Month: Soluble Nogo-Receptor-Fc decoy (AXER-204) in patients with chronic cervical spinal cord injury in the USA

      September 1, 2023

      Paper of the Month

      Research Paper of the Month: Soluble Nogo-Receptor-Fc decoy (AXER-204) in patients with chronic cervical spinal cord injury in the USA

      September 1, 2023

      Paper of the Month One glowing light bulb that stands out from unlit or dim lamps on a blue background

      Research Highlights of the Month – September 2023

      September 1, 2023

      Paper of the Month

      Research Paper of the Month: Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma

      July 24, 2023

      Paper of the Month One glowing light bulb that stands out from unlit or dim lamps on a blue background

      Research Highlight of the Month – July 2023

      July 24, 2023

      Neurology updates

      Performance of the 2017 and 2010 Revised McDonald Criteria in Predicting MS Diagnosis After a Clinically Isolated Syndrome – A MAGNIMS Study

      September 26, 2022

      Neurology updates

      Relapse-independent disability worsening plays a relevant role in every disease phase of MS

      September 26, 2022

      Neurology updates

      Epstein-Barr virus infection is a major risk factor for the development of multiple sclerosis

      September 26, 2022

      Neurology updates

      Glymphatic system impairment may contribute to multiple sclerosis pathology

      September 23, 2022

      COVID-19

      COVID-19 Research Round-Up: Literature reviews – April 2023

      April 26, 2023

      COVID-19

      COVID-19 Research Round-Up: Cross-Sectional Case Control Studies – April 2023

      April 26, 2023

      COVID-19

      COVID-19 Research Round-Up: Case Series/Case Reports – April 2023

      April 26, 2023

      COVID-19

      COVID-19 Research Round-Up: Literature reviews – March 2023

      March 16, 2023

      Eur J Neurol

      European Journal of Neurology to be fully open access from January 1 2024

      September 7, 2023

      Eur J Neurol

      Reasons to publish open access with European Journal of Neurology

      August 24, 2023

      Eur J Neurol

      Video Interview: European Journal of Neurology Award winner, Dr. Jonathan Coutinho

      July 18, 2022

      Eur J Neurol

      EAN NeuroCOVID-19 Task Force position paper on COVID-19 vaccination hesitancy among people with chronic neurological disorders

      May 2, 2022

      Scientific Corner

      New EAN Coordinating Panel on Functional Neurological Disorders – Call for Applications

      September 7, 2023

      Scientific Corner

      Special Session on Guidelines at the EAN Congress: Meet the new EAN Guidelines

      July 21, 2023

      Scientific Corner

      EAN Guideline Education and Cost-Conscious Healthcare (CoCoCare) kick-off workshop in Budapest 2023

      July 21, 2023

      Scientific Corner

      EAN Guidelines Workshop 2023: From questions to recommendations

      July 21, 2023

  • Educational
    • All eLearning Student Corner Resident and Research Fellows Fellowship reports Education corner
      Education corner Close up photo of a Black graduation cap and yellow tassel

      European Board Exam in Neurology – how to take it and how to help out

      September 20, 2023

      Resident and Research Fellows

      Research Fellowship Report 2022 – Oxford Autoimmune Neurology Group

      September 16, 2023

      Resident and Research Fellows

      Research Fellowship Report 2022 – Centre Hospitalier Universitaire Vaudois, Lausanne

      September 15, 2023

      Resident and Research Fellows

      Research Fellowship Report 2022 – Department of Neuromuscular Diseases Institute, University College London

      September 14, 2023

      eLearning

      World Brain Day with the European Academy of Neurology

      July 21, 2023

      eLearning

      New eanCampus content especially for EAN 2023

      June 30, 2023

      eLearning

      eanCampus: An Award-Winning e-Learning Experience

      June 28, 2023

      eLearning

      One year of the eanCampus – An Interview with the e-Learning Editorial Board

      June 27, 2023

      Student Corner

      Student Teaser Fellowship reports 2022 – Pisa, London, & Lausanne

      September 13, 2023

      Student Corner Illustration of a vertical pencil point on a blue background, with a yellow light bulb above it

      Student Corner: My EAN Congress experience

      September 5, 2023

      Student Corner

      Student Teaser Fellowship reports 2022 – Rotterdam, London, & Paris

      August 22, 2023

      Student Corner

      Student Teaser Fellowship winners 2023

      June 28, 2023

      Resident and Research Fellows

      Research Fellowship Report 2022 – Oxford Autoimmune Neurology Group

      September 16, 2023

      Resident and Research Fellows

      Research Fellowship Report 2022 – Centre Hospitalier Universitaire Vaudois, Lausanne

      September 15, 2023

      Resident and Research Fellows

      Research Fellowship Report 2022 – Department of Neuromuscular Diseases Institute, University College London

      September 14, 2023

      Resident and Research Fellows

      Application deadline approaching for 2024 EAN Clinical Fellowships

      September 7, 2023

      Fellowship reports

      Research Fellowship Report 2022 – Oxford Autoimmune Neurology Group

      September 16, 2023

      Fellowship reports

      Research Fellowship Report 2022 – Centre Hospitalier Universitaire Vaudois, Lausanne

      September 15, 2023

      Fellowship reports

      Research Fellowship Report 2022 – Department of Neuromuscular Diseases Institute, University College London

      September 14, 2023

      Fellowship reports

      Student Teaser Fellowship reports 2022 – Pisa, London, & Lausanne

      September 13, 2023

      Education corner Close up photo of a Black graduation cap and yellow tassel

      European Board Exam in Neurology – how to take it and how to help out

      September 20, 2023

      Education corner

      Research Fellowship Report 2022 – Oxford Autoimmune Neurology Group

      September 16, 2023

      Education corner

      Research Fellowship Report 2022 – Centre Hospitalier Universitaire Vaudois, Lausanne

      September 15, 2023

      Education corner

      Research Fellowship Report 2022 – Department of Neuromuscular Diseases Institute, University College London

      September 14, 2023

  • Other News
    • All EAN Staff EBC News in general Surveys
      EAN Staff

      EAN Head Office Profiles: Kathrin & Sasha

      August 28, 2023

      General interest

      WHO’s Intersectoral Global Action Plan on epilepsy and other neurological disorders (IGAP) published in all six UN languages

      August 3, 2023

      EAN Staff Anja Sander receiving flowers at the end of EAN Congress 2023

      Celebrating 20 Years of Excellence: Anja Sander, EAN’s Executive Director!

      August 3, 2023

      EAN News

      WHO recognises the public health need for effective and affordable treatments for multiple sclerosis

      August 3, 2023

      EAN Staff

      EAN Head Office Profiles: Kathrin & Sasha

      August 28, 2023

      EAN Staff Anja Sander receiving flowers at the end of EAN Congress 2023

      Celebrating 20 Years of Excellence: Anja Sander, EAN’s Executive Director!

      August 3, 2023

      EAN Staff

      EAN Head Office Profiles: Dauren & Benita

      June 5, 2023

      EAN Staff

      EAN Head Office Profiles: Kristián & Anna

      May 2, 2023

      EBC

      Brain Innovation Days: Discover the early programme and register today!

      July 21, 2023

      EBC

      Join the community’s calls for a European Brain Research and Innovation Plan

      July 21, 2023

      EBC

      EBC & EFPIA launch RETHINKING Alzheimer’s disease White Paper

      March 22, 2023

      EBC

      Registration and call for abstracts launched for 2023 Brain Innovation Days

      March 21, 2023

      News in general

      WHO’s Intersectoral Global Action Plan on epilepsy and other neurological disorders (IGAP) published in all six UN languages

      August 3, 2023

      News in general

      WHO recognises the public health need for effective and affordable treatments for multiple sclerosis

      August 3, 2023

      News in general

      Brain Innovation Days: Discover the early programme and register today!

      July 21, 2023

      News in general

      Join the community’s calls for a European Brain Research and Innovation Plan

      July 21, 2023

      Surveys

      Neurorehabilitation Across Europe after Ischemic and Traumatic Brain Injuries: a survey to increase knowledge on brain-injury-specific neurorehabilitation

      July 14, 2023

      Surveys

      ILAE survey on genetic testing in the epilepsies

      July 14, 2023

      Surveys

      COVID-19 and neurology: a survey of previous and continued restrictions on clinical practice, professional education and neuroeconomics

      March 3, 2023

      Surveys

      Help EAN contribute towards the development of a European Pain Research strategy

      December 5, 2022

  • EAN
  • Congress 2023
  • EANpages
  • EAN Campus
  • Eur J Neurol
  • Virtual Congress

eanpages

  • General interest
    • All Executive Page EAN News EAN Congress news Interviews
      Executive Page

      Executive Page: Advocacy for brain health gaining momentum across the neurological landscape

      October 1, 2023

      EAN News

      EAN Contributes to Global Brain Health Agenda at UNGA78 with Leadership Presence

      September 28, 2023

      EAN News

      Earthquake in Morocco – EAN Statement

      September 11, 2023

      EAN News

      New EAN Coordinating Panel on Functional Neurological Disorders – Call for Applications

      September 7, 2023

      Executive Page

      Executive Page: Advocacy for brain health gaining momentum across the neurological landscape

      October 1, 2023

      Executive Page Dear EAN members, dear friends, It is my pleasure to give you an update on behalf of the EAN Scientific Committee following a busy year since my appointment as chair. It has been a privilege to be so deeply involved in the scientific activities of the EAN and to work closely with an amazing community of people who are so dedicated to the advancement of neurology. One of the strongest threads within that community is the EAN’s group of Scientific Panels, which are often referred to as the organisation’s ‘scientific backbone’. The panels have a hand in everything the EAN does from a scientific point of view, including coordinating clinical research, disseminating good practice, assisting in planning the EAN annual congress, supporting the EAN’s educational efforts, and producing guidelines that assist neurologists in daily practice. All of this work requires a considerable amount of oversight, and this is why each panel is run by its own Management Group, elected by the panel members. Being a part of one of these Management Groups (PDF) is an opportunity to play a direct part in determining the direction of scientific progress within Europe, and I am excited to say that the call for applications to stand for election will be announced in September. All panel members and EAN individual members are eligible to apply to be candidates, with the vote being held among the existing panel members in autumn. I would like to urge every neurologist with a passion for the scientific future of their special area of interest to consider standing for election to the relevant Management Group and to look out for the call for applications later this month. I can tell you from personal experience that fulfilling a role such as this within the structure of the EAN is a fascinating and extremely rewarding experience. The chance to take on such a unique leadership position should not be missed! The most satisfying aspect of being involved in the EAN’s organisational structure is surely seeing all the hard work and planning come to fruition when a small idea evolves into a newly launched project. One such example is the 1st EAN Science School, taking place in Salzburg next March. The idea of the Science School is to offer early career neurologists with an interest in translational research a new avenue for learning about basic pathomechanisms of neurological disorders. Application for this very first edition, on ‘Pathophysiology of disorders of the nervous system’, closed last week and we have been delighted with the level of interest. It was a pleasure to be part of the task force in charge of planning this new project and I look forward to seeing it officially transferred to the hands of the Scientific Committee after a successful event and evaluation in spring. Of our ongoing activities, one of the most significant is the EAN Neuro-covid Registry, which aims to collate epidemiological data on neurological manifestations in patients with COVID-19 infection reported by neurologists in outpatient services, emergency rooms, and hospital departments. We currently have 1,542 patients entered in the database, from 35 centres across 23 countries. So far, 29 patients have been followed for 12 months and 387 have completed the 6-months follow up. This is a decent start, but I would like to strongly encourage EAN members and their institutions to get involved and contribute cases to what will become an invaluable resource for neurologists and clinicians to improve care for Covid-19 patients. Finally, I would like share a word on a forthcoming collaboration between EAN and the Human Brain Project in December, that I think will interest a lot of EAN members. The EAN-EBRAINS joint workshop on ‘The future of medical data sharing in clinical neurosciences’ will be a three-day virtual event that aims to discuss issues and challenges associated with data sharing in Europe, from ethics to data safety and privacy, including those specific to data federation, such as the development and validation of federated algorithms. The whole workshop is completely free of charge and registration is open until 25 November, so please check out the details and sign up! I wish you all a healthy and pleasant autumn and I look forward to updating you again. Best wishes Thomas Berger Chair of the EAN Scientific Committee

      Executive Page: Management Group elections are coming – run for office and help shape our future!

      September 1, 2023

      Executive Page

      Executive Page: Thank you for making the EAN Congress 2023 a great success!

      July 24, 2023

      Executive Page

      Executive Page: Get ready for EAN 2023 in Budapest!

      June 1, 2023

      EAN News

      Executive Page: Advocacy for brain health gaining momentum across the neurological landscape

      October 1, 2023

      EAN News

      EAN Contributes to Global Brain Health Agenda at UNGA78 with Leadership Presence

      September 28, 2023

      EAN News

      Earthquake in Morocco – EAN Statement

      September 11, 2023

      EAN News

      New EAN Coordinating Panel on Functional Neurological Disorders – Call for Applications

      September 7, 2023

      EAN Congress news

      African Academy of Neurology features in Special Studio Session at EAN 2023

      July 25, 2023

      EAN Congress news

      Find photos, facts, figures and reports in our EAN Congress Review

      July 24, 2023

      EAN Congress news

      Executive Page: Thank you for making the EAN Congress 2023 a great success!

      July 24, 2023

      EAN Congress news

      Special Session on Guidelines at the EAN Congress: Meet the new EAN Guidelines

      July 21, 2023

      Interviews

      Video Interview: Prof. Mary Reilly, Moritz Romberg lecturer at EAN 2023

      July 4, 2023

      Interviews

      Video Interview: Mark Hallett, C. Brown-Séquard lecturer at EAN 2023

      July 3, 2023

      Interviews

      Video Interview: Josep Dalmau, Camillo Golgi Lecturer at EAN 2023

      July 2, 2023

      Interviews

      Video Interview: Dementia & Cognitive Disorders Panel Co-Chairs

      September 8, 2022

  • Academic/Scientific
    • All Paper of the Month Neurology updates COVID-19 Eur J Neurol Scientific Corner
      Academic/Scientific

      Open Call: EMA seeks new data partners for DARWIN EU – deadline 31 October

      September 29, 2023

      EAN News

      New EAN Coordinating Panel on Functional Neurological Disorders – Call for Applications

      September 7, 2023

      EAN News

      European Journal of Neurology to be fully open access from January 1 2024

      September 7, 2023

      Paper of the Month

      Research Paper of the Month: Soluble Nogo-Receptor-Fc decoy (AXER-204) in patients with chronic cervical spinal cord injury in the USA

      September 1, 2023

      Paper of the Month

      Research Paper of the Month: Soluble Nogo-Receptor-Fc decoy (AXER-204) in patients with chronic cervical spinal cord injury in the USA

      September 1, 2023

      Paper of the Month One glowing light bulb that stands out from unlit or dim lamps on a blue background

      Research Highlights of the Month – September 2023

      September 1, 2023

      Paper of the Month

      Research Paper of the Month: Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma

      July 24, 2023

      Paper of the Month One glowing light bulb that stands out from unlit or dim lamps on a blue background

      Research Highlight of the Month – July 2023

      July 24, 2023

      Neurology updates

      Performance of the 2017 and 2010 Revised McDonald Criteria in Predicting MS Diagnosis After a Clinically Isolated Syndrome – A MAGNIMS Study

      September 26, 2022

      Neurology updates

      Relapse-independent disability worsening plays a relevant role in every disease phase of MS

      September 26, 2022

      Neurology updates

      Epstein-Barr virus infection is a major risk factor for the development of multiple sclerosis

      September 26, 2022

      Neurology updates

      Glymphatic system impairment may contribute to multiple sclerosis pathology

      September 23, 2022

      COVID-19

      COVID-19 Research Round-Up: Literature reviews – April 2023

      April 26, 2023

      COVID-19

      COVID-19 Research Round-Up: Cross-Sectional Case Control Studies – April 2023

      April 26, 2023

      COVID-19

      COVID-19 Research Round-Up: Case Series/Case Reports – April 2023

      April 26, 2023

      COVID-19

      COVID-19 Research Round-Up: Literature reviews – March 2023

      March 16, 2023

      Eur J Neurol

      European Journal of Neurology to be fully open access from January 1 2024

      September 7, 2023

      Eur J Neurol

      Reasons to publish open access with European Journal of Neurology

      August 24, 2023

      Eur J Neurol

      Video Interview: European Journal of Neurology Award winner, Dr. Jonathan Coutinho

      July 18, 2022

      Eur J Neurol

      EAN NeuroCOVID-19 Task Force position paper on COVID-19 vaccination hesitancy among people with chronic neurological disorders

      May 2, 2022

      Scientific Corner

      New EAN Coordinating Panel on Functional Neurological Disorders – Call for Applications

      September 7, 2023

      Scientific Corner

      Special Session on Guidelines at the EAN Congress: Meet the new EAN Guidelines

      July 21, 2023

      Scientific Corner

      EAN Guideline Education and Cost-Conscious Healthcare (CoCoCare) kick-off workshop in Budapest 2023

      July 21, 2023

      Scientific Corner

      EAN Guidelines Workshop 2023: From questions to recommendations

      July 21, 2023

  • Educational
    • All eLearning Student Corner Resident and Research Fellows Fellowship reports Education corner
      Education corner Close up photo of a Black graduation cap and yellow tassel

      European Board Exam in Neurology – how to take it and how to help out

      September 20, 2023

      Resident and Research Fellows

      Research Fellowship Report 2022 – Oxford Autoimmune Neurology Group

      September 16, 2023

      Resident and Research Fellows

      Research Fellowship Report 2022 – Centre Hospitalier Universitaire Vaudois, Lausanne

      September 15, 2023

      Resident and Research Fellows

      Research Fellowship Report 2022 – Department of Neuromuscular Diseases Institute, University College London

      September 14, 2023

      eLearning

      World Brain Day with the European Academy of Neurology

      July 21, 2023

      eLearning

      New eanCampus content especially for EAN 2023

      June 30, 2023

      eLearning

      eanCampus: An Award-Winning e-Learning Experience

      June 28, 2023

      eLearning

      One year of the eanCampus – An Interview with the e-Learning Editorial Board

      June 27, 2023

      Student Corner

      Student Teaser Fellowship reports 2022 – Pisa, London, & Lausanne

      September 13, 2023

      Student Corner Illustration of a vertical pencil point on a blue background, with a yellow light bulb above it

      Student Corner: My EAN Congress experience

      September 5, 2023

      Student Corner

      Student Teaser Fellowship reports 2022 – Rotterdam, London, & Paris

      August 22, 2023

      Student Corner

      Student Teaser Fellowship winners 2023

      June 28, 2023

      Resident and Research Fellows

      Research Fellowship Report 2022 – Oxford Autoimmune Neurology Group

      September 16, 2023

      Resident and Research Fellows

      Research Fellowship Report 2022 – Centre Hospitalier Universitaire Vaudois, Lausanne

      September 15, 2023

      Resident and Research Fellows

      Research Fellowship Report 2022 – Department of Neuromuscular Diseases Institute, University College London

      September 14, 2023

      Resident and Research Fellows

      Application deadline approaching for 2024 EAN Clinical Fellowships

      September 7, 2023

      Fellowship reports

      Research Fellowship Report 2022 – Oxford Autoimmune Neurology Group

      September 16, 2023

      Fellowship reports

      Research Fellowship Report 2022 – Centre Hospitalier Universitaire Vaudois, Lausanne

      September 15, 2023

      Fellowship reports

      Research Fellowship Report 2022 – Department of Neuromuscular Diseases Institute, University College London

      September 14, 2023

      Fellowship reports

      Student Teaser Fellowship reports 2022 – Pisa, London, & Lausanne

      September 13, 2023

      Education corner Close up photo of a Black graduation cap and yellow tassel

      European Board Exam in Neurology – how to take it and how to help out

      September 20, 2023

      Education corner

      Research Fellowship Report 2022 – Oxford Autoimmune Neurology Group

      September 16, 2023

      Education corner

      Research Fellowship Report 2022 – Centre Hospitalier Universitaire Vaudois, Lausanne

      September 15, 2023

      Education corner

      Research Fellowship Report 2022 – Department of Neuromuscular Diseases Institute, University College London

      September 14, 2023

  • Other News
    • All EAN Staff EBC News in general Surveys
      EAN Staff

      EAN Head Office Profiles: Kathrin & Sasha

      August 28, 2023

      General interest

      WHO’s Intersectoral Global Action Plan on epilepsy and other neurological disorders (IGAP) published in all six UN languages

      August 3, 2023

      EAN Staff Anja Sander receiving flowers at the end of EAN Congress 2023

      Celebrating 20 Years of Excellence: Anja Sander, EAN’s Executive Director!

      August 3, 2023

      EAN News

      WHO recognises the public health need for effective and affordable treatments for multiple sclerosis

      August 3, 2023

      EAN Staff

      EAN Head Office Profiles: Kathrin & Sasha

      August 28, 2023

      EAN Staff Anja Sander receiving flowers at the end of EAN Congress 2023

      Celebrating 20 Years of Excellence: Anja Sander, EAN’s Executive Director!

      August 3, 2023

      EAN Staff

      EAN Head Office Profiles: Dauren & Benita

      June 5, 2023

      EAN Staff

      EAN Head Office Profiles: Kristián & Anna

      May 2, 2023

      EBC

      Brain Innovation Days: Discover the early programme and register today!

      July 21, 2023

      EBC

      Join the community’s calls for a European Brain Research and Innovation Plan

      July 21, 2023

      EBC

      EBC & EFPIA launch RETHINKING Alzheimer’s disease White Paper

      March 22, 2023

      EBC

      Registration and call for abstracts launched for 2023 Brain Innovation Days

      March 21, 2023

      News in general

      WHO’s Intersectoral Global Action Plan on epilepsy and other neurological disorders (IGAP) published in all six UN languages

      August 3, 2023

      News in general

      WHO recognises the public health need for effective and affordable treatments for multiple sclerosis

      August 3, 2023

      News in general

      Brain Innovation Days: Discover the early programme and register today!

      July 21, 2023

      News in general

      Join the community’s calls for a European Brain Research and Innovation Plan

      July 21, 2023

      Surveys

      Neurorehabilitation Across Europe after Ischemic and Traumatic Brain Injuries: a survey to increase knowledge on brain-injury-specific neurorehabilitation

      July 14, 2023

      Surveys

      ILAE survey on genetic testing in the epilepsies

      July 14, 2023

      Surveys

      COVID-19 and neurology: a survey of previous and continued restrictions on clinical practice, professional education and neuroeconomics

      March 3, 2023

      Surveys

      Help EAN contribute towards the development of a European Pain Research strategy

      December 5, 2022

Forum

Neurological News from Denmark IV – the land of the 2nd EAN congress 2016: Research in multiple sclerosis in Denmark.

February 1, 2016

Nils Koch-Henriksen 012016Per Soelberg Sørensenby Nils Koch-Henriksen and Per Soelberg Sørensen

Denmark has a 100-year history of research in multiple sclerosis (MS), but as everywhere, the number of published studies has grown almost exponentially during the last two decades.

Multiple sclerosis pathological anatomy

One of the significant Danish contributors to multiple sclerosis (MS) research in the 20th century was Torben Fog. His most important publications was about the pathological anatomy of MS lesions in the spinal cord and brain(1;2), based on a collection of brain and spinal cord specimens from autopsies of persons with MS. Torben Fog’s pioneering work was taken up decades later by researchers from the Danish Multiple Sclerosis Center and Department of Neuropathology, Rigshospitalet, who in collaboration with Institute for Brain Research in Vienna, using tissue specimens collected by Torben Fog, studied the dynamic evolution of inflammation and remyelination and found a close association between ongoing inflammation and neurodegeneration. In patients, in whom inflammation had subsided, no sign of ongoing acute axonal damage could be found. They also showed that remyelinated areas had increased vulnerability(3).

The Danish Multiple Sclerosis Registry (DMSR)

In 1948 Dr. Kay Hyllested started his nationwide survey of the occurrence of MS in Denmark where the conditions for were in particular suitable for epidemiologic research because all Danish citizens were kept in the local national registers. Hyllested used multiple sources and estimated the point prevalence in 1949 in Denmark at 65/100,000,(4) and later established the DMSR, which has ever since been continuously updated with virtually complete onset cohorts covering the years from 1948 up to recently. Since 1986 the DMSR has been associated with National Institute for Public Health, Copenhagen and is associated with the Danish Multiple Sclerosis Center, Rigshospitalet, Copenhagen. Later, the Registry was staffed by the neurologists N.K-H and Egon Stenager, who together have authored a number of published papers based on the register.
The DMSR has published a number of studies concerning descriptive epidemiology (prevalence and incidence) and has confirmed that the increasing trend in female incidence (nearly a doubling)(6;7) and sex ratio(8) is also true for the Danish population. A review of the research associated with the Danish MS Registry has recently been published(5).
Follow-up studies. The DMSR is primarily an epidemiological register with no systematic clinical follow-up, but a number of endpoints for all citizens can be achieved by linkage of the DMSG to the Civil Registration System, e.g. vital status and date of death of all deceased MS persons and causes of death. The median survival time in MS patients was 31 years, 10 years shorter than in a matched background population, but survival had improved significantly over decades significantly more than in the matched background population.(9) The risk of suicide among persons with multiple sclerosis was more than twice that of the population.(10) The median time from onset to early pension was 10 years for MS patients versus 24 years for matched controls.(11)
Association studies. Denmark has several population based registers, many of them the under Statistics Denmark. This has enabled a number of register linkage studies where association between certain physical and environmental exposures and the risk of MS have been determined in comparison with the background population. All the below mentioned studies were based on register linkage and not on questionnaires.5
Some examples of “positive” register studies. 1) All persons, registered over decades by a national laboratory with infectious mononucleosis by heterophile andibody test had a 2.7 times increased risk of MS later in life. 2) The risk for MS was increased in first-degree relatives of patients with Hodgkin lymphoma. 3) The risk of developing MS in patients with type 1 diabetes was three-fold increased. 4) The overall risk for cancers was 16% reduced in men. 5) High body mass index in school children carried an increased risk of MS in adulthood. Childbirths apparently carried a decreased risk of onset of in the subsequent five years. Use of antibiotics was associated by an increased risk of MS.
Some examples of “negative” register studies: Formerly suspected risk factors for MS could be exonerated, e.g. socioeconomic status in childhood or in adulthood; childhood infections; head injury; exposure to electromagnetic fields in utility workers; being a nurse or nurse anaesthetist; and exposure to organic solvents.

 Treatment Register

The Danish Treatment MS Register was established in 1996 as a separate entity adjoined the Danish MS Registry. It contains prospectively collected data on all patients in Denmark who have received disease modifying therapy. The register is overseen by the Danish Multiple Sclerosis Group representing neurologist from all MS treating centres in Denmark.
A nationwide study comprising 2393 patients, who had started immunomodulatory therapy from 1996 to 2003, reported treatment response in patients treated with various immunomodulatory therapies.(12) Presence of NAbs proved to increase the relapse rates considerably. Studies of the dynamics of NAbs disclosed that NAbs, if present, always occurred within the first 2 years of treatment and that a considerable proportion of patients, in particular patients treated with IFN-beta 1b, became Nab-negative during continued therapy with IFN-beta.(13) It was clearly shown that NAbs hampered the IFN-beta bioactivity and treatment effect on MRI, and, in fact, patients with high titres of NAbs and without in vivo MxA-induction after injection of IFN-beta did not show any differential expression of more than 1.000 genes after an injection of IFN-beta.
The Danish Multiple Sclerosis Center at Rigshospitalet became among the world’s leading centres for measuring NAbs and studying the effect of NAbs that has translated into the publication of “Guidelines on use of Anti-interferon-beta Antibody Measurement in MS” issued by the European Federation of Neurological Societies.(14)

Clinical and translational research (Danish Multiple Sclerosis Center)

During the last 20 years, clinical and translational MS research in Denmark has been centred at the Danish Multiple Sclerosis Center at Rigshospitalet, Copenhagen from which several single-centre and multi-centre clinical trials were initiated and directed. A placebo-controlled trial of plasma exchange combined with azathioprine in secondary progressive MS did not show any effect on MRI lesions. Intravenous immunoglobulin decreased gadolinium enhancing lesions on serial MRI and reduced the number of patients with clinical exacerbations. Two large international placebo-controlled multi-centre trials showed that methylprednisolone as add-on therapy to IFN-beta 1a significantly decreased the number of clinical relapses,(15) whereas simvastatin as add-on therapy to IFN-beta 1a did not show any effect on relapse rate or MRI lesions.(16) In an open-label single-centre study in patients with primary or secondary progressive MS natalizumab decreased CSF biomarkers of inflammation, axonal damage, and demyelination (osteopontin, neurofilament light, and myelin basic protein) and increased the magnetization transfer ratio in both cortical grey and normal appearing white matter.(17) In a small observational study of orally administered Trichuris Suis ova at 2-week intervals for 12 weeks did not show any beneficial effect on serial MRI or relapses.(18)

The Danish Multiple Sclerosis Center was also lead investigator in the first clinical placebo-controlled study of the anti-CD20 monoclonal antibody ofatumumab in relapsing remitting MS that showed a profound effect on MRI activity compared with placebo.
New immunological and translational studies have shown that high CSF concentration of chemokine CXCL13 was associated with disease activity in MS.(19) Increased spontaneous expression of MX1 and other genes associated with IFN-beta activity correlated with the expression of FOXP3 and IL10 expression and were associated with less disease activity on MRI. IFN-beta treatment and endogenous type I IFN activity had similar effect on VLA-4 expression and were associated with control of disease activity.(20) Spontaneous expression of IFN-beta inducible genes in peripheral blood mononuclear cells and treatment with interferon-beta were associated with reduced myelin basic protein-induced T-cell responses in vitro.
A study of 1,161 Danish MS patients revealed that younger age of onset of MS was associated with low exposure of summer sun in adolescence, higher body mass index at 20 years of age.(21)
An early genetic study indicated multiple sclerosis susceptibility loci on chromosomes 5P and 6P21,(22) and a study of co-effected sib pairs from Denmark, Norway and Sweden suggested that disease course an age of onset are partly under genetic control.

By using positron emission tomography to study the cerebral metabolic rate of glucose it was found that both global and regional cortical cerebral metabolic rate of glucose was reduced significantly in MS patients, and correlated with the total lesion area in T2 weighted MRI and cognitive dysfunction,(23) and the cortical cerebral metabolism in MS decreased significantly during a 2 year observation period.

everal important studies of patients with optic neuritis have been made at the MS Clinic, Glostrup Hospital. A controlled trial of oral high dose methylprednisolone in acute optic neuritis showed an improved recovery at 1 and 3 weeks but no difference from placebo could be demonstrated after 8 weeks.(24) Using optical coherence tomography and MRI it was shown that retinal nerve fibre layer thickness was associated with the lesion length in optic neuritis.

Research form University of Aarhus

A research team under University of Aarhus has studied the effect of resistance training in patients with MS. Twelve weeks of intense progressive resistance training of the lower extremities led to improvement of muscle strength and functional capacity, and the effect persisted after 12 weeks.(25) Basal research is outside the scope of this review, but virus research from University of Aarhus has provided studies on the role of endogenous retroviruses, Epstein-Barr viruses, and human herpes viruses.(26)

Reference List

(1) Fog T. [Rygmarvens patologiske anatomi ved dissemineret sclerose og ved dissemineret encephalomyelitis]. Copenhagen: Munksgaard, 1948.
(2) Fog T. The topography of plaques in multiple sclerosis with special reference to cerebral plaques. Acta Neurol Scand Suppl 1965;15:1-161.
(3) Bramow S, Frischer JM, Lassmann H et al. Demyelination versus remyelination in progressive multiple sclerosis. Brain 2010;133:2983-2998.
(4) Hyllested K. Disseminated sclerosis en Denmark: Prevalence and geographical distribution (Doctoral thesis). Copenhagen: J. Jorgensen, 1956.
(5) Koch-Henriksen N, Magyari M, Laursen B. Registers of multiple sclerosis in Denmark. Acta Neurol Scand Suppl 2015;132:4-10.
(6) Koch-Henriksen N, Bronnum-Hansen H, Hyllested K. Incidence of multiple sclerosis in Denmark 1948-1982: a descriptive nationwide study. Neuroepidemiology 1992;11:1-10.
(7) Koch-Henriksen N, Stenager E, Bronnum-Hansen H, Flachs EM. Increasing incidence of Multiple sclerosis in Danish women [abstract]. Mult Scler 2006;12 (suppl 1):S228.
(8) Koch-Henriksen N, Sorensen PS. The changing demographic pattern of multiple sclerosis epidemiology. Lancet Neurol 2010;9:520-532.
(9) Bronnum-Hansen H, Koch-Henriksen N, Stenager E. Trends in survival and cause of death in Danish patients with multiple sclerosis. Brain 2004;127:844-850.
(10) Bronnum-Hansen H, Stenager E, Nylev SE, Koch-Henriksen N. Suicide among Danes with multiple sclerosis. J Neurol Neurosurg Psychiatry 2005;76:1457-1459.
(11) Pfleger CC, Flachs EM, Koch-Henriksen N. Social consequences of multiple sclerosis (1): early pension and temporary unemployment–a historical prospective cohort study. Mult Scler 2010;16:121-126.
(12) Sorensen PS, Koch-Henriksen N, Ravnborg M et al. Immunomodulatory treatment of multiple sclerosis in denmark: a prospective nationwide survey. Mult Scler 2006;12:253-264.
(13) Sorensen PS, Koch-Henriksen N, Ross C, Clemmesen KM, Bendtzen K. Appearance and disappearance of neutralizing antibodies during interferon-beta therapy. Neurology 2005;65:33-39.
(14) Sorensen PS, Deisenhammer F, Duda P et al. Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis. Eur J Neurol 2005;12:817-827.
(15) Sorensen PS, Mellgren SI, Svenningsson A et al. NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial. Lancet Neurol 2009;8:519-529.
(16) Sorensen PS, Lycke J, Eralinna JP et al. Simvastatin as add-on therapy to interferon beta-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial. Lancet Neurol 2011;10:691-701.
(17) Romme CJ, Ratzer R, Bornsen L et al. Natalizumab in progressive MS: results of an open-label, phase 2A, proof-of-concept trial. Neurology 2014;82:1499-1507.
(18) Voldsgaard A, Bager P, Garde E et al. Trichuris suis ova therapy in relapsing multiple sclerosis is safe but without signals of beneficial effect. Mult Scler 2015.
(19) Sellebjerg F, Bornsen L, Khademi M et al. Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS. Neurology 2009;73:2003-2010.
(20) Sellebjerg F, Krakauer M, Limborg S et al. Endogenous and recombinant type I interferons and disease activity in multiple sclerosis. PLoS One 2012;7:e35927.
(21) Laursen JH, Sondergaard HB, Sorensen PS, Sellebjerg F, Oturai AB. Association between age at onset of multiple sclerosis and vitamin D level-related factors. Neurology 2015.
(22) Oturai A, Larsen F, Ryder LP et al. Linkage and association analysis of susceptibility regions on chromosomes 5 and 6 in 106 Scandinavian sibling pair families with multiple sclerosis. Ann Neurol 1999;46:612-616.
(23) Blinkenberg M, Rune K, Jensen CV et al. Cortical cerebral metabolism correlates with MRI lesion load and cognitive dysfunction in MS. Neurology 2000;54:558-564.
(24) Sellebjerg F, Nielsen HS, Frederiksen JL, Olesen J. A randomized, controlled trial of oral high-dose methylprednisolone in acute optic neuritis. Neurology 1999;52:1479-1484.
(25) Dalgas U, Stenager E, Jakobsen J et al. Resistance training improves muscle strength and functional capacity in multiple sclerosis. Neurology 2009;73:1478-1484.
(26) Haahr S, Sommerlund M, Moller-Larsen A, Nielsen R, Hansen HJ. Just another dubious virus in cells from a patient with multiple sclerosis? Lancet 1991;337:863-864.

Nils Koch-Henriksen is Professor of Neurology at the Danish MS Research Center – Rigshospitalet, Copenhagen, Denmark
Per Soelberg Sørensen is EAN member at Large and Professor of Neurology at the University of Copenhagen, Rigshospitalet, Copenhagen, Denmark

Neurological News from Denmark IV – the land of the 2nd EAN congress 2016: Research in multiple sclerosis in Denmark. was last modified: November 14th, 2018 by Editor
Share this...
Share on Facebook
Facebook
Tweet about this on Twitter
Twitter
Share on LinkedIn
Linkedin
multiple sclerosishistorydenmarkDanish Multiple Sclerosis
previous post
European Journal of Neurology: CME article February 2016
next post
Paper of the month: Efficacy and safety of andexanet to reverse factor Xa inhibitors activity.

You may also like

EAN signs the Alzheimer Europe Glasgow Declaration

August 1, 2015

EAN CALL FOR APPLICATIONS! Neuropenews Chief Editor & Website Chief Editor

August 19, 2014

Science from a Tweet: a frightening speculation

September 1, 2015

Forum: The EFNS/ENS Liaison Committee – who we are and what we do

March 1, 2013

Neurology in Turkey – the land of EFNS/ENS 2014: Past and present

May 1, 2014

Forum: Science from a Tweet: ever thought about Meta-Research?

April 1, 2014

Science from a Tweet: let them invade and save us

December 1, 2015

Neurological News from Germany – the land of the 1st EAN congress in 2015

November 1, 2014

Science from a Tweet: close to the heart

October 1, 2015

Science from a Tweet: Experimental Ebola drug ZMapp raises big ethical issues, we need to think both ‘carefully & humanistically’

September 1, 2014

Leave a Comment Cancel Reply

You need to be logged in to comment. Please login to MyEAN on top.

EANcore COVID-19

Upcoming Events

Oct
3
Tue
all-day 28th International Annual Congre...
28th International Annual Congre...
Oct 3 – Oct 7 all-day
The 28th International Annual Congress of the World Muscle Society will take place on 3–7 October 2023, in Charleston, South Carolina, United States. For more information, visit https://www.wms2023.com/ Share this...FacebookTwitterLinkedin
Oct
4
Wed
all-day eSleep Europe (European Sleep Re...
eSleep Europe (European Sleep Re...
Oct 4 – Oct 6 all-day
eSleep Europe (European Sleep Research Society)
Don’t miss the ESRS/EAN Joint Session with interactive clinical cases on Friday, 6 October, 10:30-11:30. For further details on the programme of this joint session click here Please note that…
Oct
11
Wed
all-day The 9th Joint ECTRIMS-ACTRIMS Me...
The 9th Joint ECTRIMS-ACTRIMS Me...
Oct 11 – Oct 13 all-day
The 9th Joint ECTRIMS-ACTRIMS Meeting – MSMilan2023 – is the world’s largest research meeting in multiple sclerosis. Taking place 11-13 October at Allianz MiCo in Milan, IT, offering participants a…
Oct
12
Thu
all-day EAN Autumn School 2023 in Loutra...
EAN Autumn School 2023 in Loutra...
Oct 12 – Oct 16 all-day
Dedicated to clinical neurologists in training who have not yet completed their residency/ clinical speciality training. Experienced neurologists and sub-specialists will illustrate how they approach specific clinical presentations and symptoms,…
Oct
15
Sun
all-day XXVI World Congress of Neurology
XXVI World Congress of Neurology
Oct 15 – Oct 19 all-day
Don’t miss out on the opportunity to advance your knowledge and connect with your peers at the XXVI World Congress of Neurology. Register before 25 July 2023 to secure your…
View Calendar

Latest Tweets

  • Tweet Avatar
    EANeurology
    @EANeurology
    Second Research Highlight in June: A new study reveals possible brain changes leading to post-#COVID cognitive symp… https://t.co/QauhccSxtJ

    4 months ago
  • Tweet Avatar
    EANeurology
    @EANeurology
    ⏱️ Deadline approaching - sign up by June 15 to join the Guidelines Workshop on 30 June (12:00 – 17:00 CEST) in Bud… https://t.co/UuvYecfddh

    4 months ago
  • Tweet Avatar
    EANeurology
    @EANeurology
    First Research Highlight in June: #INTERACT3 trial unveils a potential game-changer in cerebral hemorrhage treatmen… https://t.co/UQ8E8uVKXs

    4 months ago
  • Tweet Avatar
    EANeurology
    @EANeurology
    Have an interest in #ChildNeurology? Then the #EPNS2023 Congress on 20-24 June in Prague is for you! Learn about… https://t.co/HodD8HUOxe

    4 months ago
  • Tweet Avatar
    EANeurology
    @EANeurology
    Programme Committee Chair Ulf Kallweit gives a sneak preview of the upcoming #ean2023 in Budapest on 1-4 July! Vis… https://t.co/TOmMaJFbFP

    4 months ago

Keep in touch

Facebook Twitter Instagram
EAN Pages is a members service of the European Academy of Neurology https://www.ean.org

All content from January 2012 - June 2013 was published by EFNS; content from July 2013 - June 2014 by EFNS and ENS.

ISSN 2310-2934

Keep in touch

Facebook Twitter Instagram Linkedin

Archives

Pages

  • Congress 2021
  • Content Submission for EAN Pages
  • Content Submission for Social Media
  • Privacy Policy
  • About us
  • Help
  • Contact

Back To Top